| ORIGINAL ARTICLE |
|
| Year : 2016 | Volume
: 7
| Issue : 2 | Page : 42-49 |
|
|
Pattern of chromosomal aberrations and expression profile of p53ser15 and BAX protein in peripheral blood lymphocytes of healthy subjects and cancer patients
Swapnaja Gulawani1, Venkateswarlu Raavi1, S Suresh2, Venkatachalam Perumal1
1 Department of Human Genetics, Sri Ramachandra University, Porur, Chennai, Tamil Nadu, India
2 Department of Medical Oncology, SRMC and RI, Sri Ramachandra University, Porur, Chennai, Tamil Nadu, India
Correspondence Address:
Venkatachalam Perumal
Department of Human Genetics, Sri Ramachandra University, Porur, Chennai, Tamil Nadu
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0973-0168.191706
|
|
|
Introduction: Chemotherapy is an important treatment option which is used for all cancer types. The basic mechanism of action of chemotherapy is that the drugs cause damage to the cancer cells by breaking down DNA, interfere with replication, or enhance the cell killing. Emerging studies have shown that despite tremendous improvements on the therapeutic options, benefit derived from the therapy is not desirable. It is because, interindividual variations among the patient's response to therapy as well as complex signaling molecules and mechanism involved, determining the final outcome of the therapy. Therapeutic efficacy can be improved by predicting a patient response to that agent, adopting a suitable marker.
Materials and Methods: This study involves analysis of the frequencies of chromosomal aberrations and micronucleus, expression profile of p53 ser15 and BAX in healthy subjects and cancer patients, to identify a novel marker to predict their response to chemotherapy agents. For this, peripheral blood sample (4 ml) from cancer patients (solid tumors) was obtained before and after chemotherapy (n = 20). The change in those marker in cancer patients were compared with age- and sex-matched healthy subjects (n = 20).
Results: The present study results indicated substantial increase in all four biomarkers for postchemotherapy compared to that obtained before therapy; however, the increase was not significant (P > 0.05), whereas a significant increase (P < 0.05) was observed in all markers from cancer patients compared to that of healthy volunteers relate the genetic instability to the disease status. Furthermore, on comparison, the levels of all those changes are increased in samples obtained posttherapy, despite the magnitude of BAX expression is considerably higher when compared to other markers.
Conclusion: Therefore, the study results implied that BAX can be used as a better marker to predict the patient response to chemotherapy.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
![JOURNAL_FULL_NAME]](images/logo.gif){kind=logo}
